Eisai Earns First Japanese Drug On Russian Market With Epilepsy Treatment
This article was originally published in PharmAsia News
Executive Summary
Eisai has been cleared to market its epilepsy drug Zonegran (zonisamide) in Russia, giving the Japanese firm its first presence in the Russian market.